Teachers Retirement System of The State of Kentucky lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 43.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 76,442 shares of the biopharmaceutical company’s stock after selling 58,246 shares during the quarter. Teachers Retirement System of The State of Kentucky owned 0.08% of Alnylam Pharmaceuticals worth $9,712,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in the business. The Manufacturers Life Insurance Company boosted its position in Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Alnylam Pharmaceuticals by 0.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 180,058 shares of the biopharmaceutical company’s stock worth $21,156,000 after purchasing an additional 629 shares during the last quarter. Great West Life Assurance Co. Can boosted its position in shares of Alnylam Pharmaceuticals by 8.5% in the 3rd quarter. Great West Life Assurance Co. Can now owns 8,904 shares of the biopharmaceutical company’s stock worth $1,050,000 after purchasing an additional 695 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 10.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 7,200 shares of the biopharmaceutical company’s stock worth $915,000 after purchasing an additional 700 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado lifted its holdings in Alnylam Pharmaceuticals by 4.4% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 17,321 shares of the biopharmaceutical company’s stock worth $2,201,000 after acquiring an additional 736 shares in the last quarter. Institutional investors own 92.28% of the company’s stock.
ALNY has been the topic of several recent analyst reports. Goldman Sachs upgraded Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a report on Friday, December 15th. Leerink Swann lifted their price target on Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the company a “market perform” rating in a research note on Thursday, January 25th. B. Riley reaffirmed a “buy” rating and issued a $205.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, January 19th. Morgan Stanley lowered their price target on Alnylam Pharmaceuticals from $128.00 to $118.00 and set an “equal weight” rating on the stock in a research report on Friday, February 9th. Finally, Chardan Capital reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, January 19th. Four research analysts have rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and an average price target of $134.15.
Shares of NASDAQ:ALNY opened at $95.08 on Friday. The firm has a market cap of $10,246.53, a PE ratio of -17.54 and a beta of 2.68. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.23 and a quick ratio of 12.23. Alnylam Pharmaceuticals, Inc. has a 52-week low of $47.16 and a 52-week high of $153.99.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.38) by ($0.10). The company had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. The firm’s quarterly revenue was up 116.6% on a year-over-year basis. During the same quarter last year, the company posted ($1.32) earnings per share. sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.88 EPS for the current year.
In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 20,000 shares of the company’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $145.00, for a total transaction of $2,900,000.00. Following the sale, the senior vice president now owns 24,500 shares of the company’s stock, valued at $3,552,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Akshay Vaishnaw sold 88,554 shares of the stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $143.10, for a total transaction of $12,672,077.40. Following the transaction, the insider now directly owns 55,856 shares in the company, valued at approximately $7,992,993.60. The disclosure for this sale can be found here. Insiders sold 198,620 shares of company stock valued at $28,404,143 over the last 90 days. 4.30% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Teachers Retirement System of The State of Kentucky Has $9.71 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/teachers-retirement-system-of-the-state-of-kentucky-sells-58246-shares-of-alnylam-pharmaceuticals-inc-alny.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.